The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study: Rationale, design and methods

Roberto Bernabei; Emanuele Marzetti; Giovanni Gambassi; Riccardo Calvani; Jacopo Gervasoni; Aniello Primiano; Leocadio Rodriguez-Mañas; Federico Marini; Alessandra Biancolillo; Olga Laosa; Laura Pedraza; Alfredo Miccheli; Isabelle Bourdel-Marchasson; Sophie C. Regueme; Alan J. Sinclair

doi:10.1016/j.exger.2019.110782

The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study: Rationale, design and methods

Roberto Bernabei, Emanuele Marzetti, Giovanni Gambassi, Riccardo Calvani, Jacopo Gervasoni, Aniello Primiano, Leocadio Rodriguez-Mañas, Federico Marini, Alessandra Biancolillo, Olga Laosa, Laura Pedraza, Alfredo Miccheli, Isabelle Bourdel-Marchasson, Sophie C. Regueme, Alan J. Sinclair

Risultato della ricerca: Contributo in rivista › Articolo in rivista

2 Citazioni (Scopus)

Abstract

Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact geriatric condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM.

Lingua originale	English
pagine (da-a)	110782-N/A
Numero di pagine	9
Rivista	Experimental Gerontology
DOI	https://doi.org/10.1016/j.exger.2019.110782
Stato di pubblicazione	Pubblicato - 2020

Keywords

Chemometrics
Metabolic profiling
Metabolomics
Multivariate analysis
Personalized medicine
Sarcopenia

Accesso al documento

10.1016/j.exger.2019.110782

Altri file e collegamenti

Link a IRIS PubliCatt

Fingerprint Entra nei temi di ricerca di 'The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study: Rationale, design and methods'. Insieme formano una fingerprint unica.

Cita questo

Bernabei, R., Marzetti, E., Gambassi, G., Calvani, R., Gervasoni, J., Primiano, A., Rodriguez-Mañas, L., Marini, F., Biancolillo, A., Laosa, O., Pedraza, L., Miccheli, A., Bourdel-Marchasson, I., Regueme, S. C., & Sinclair, A. J. (2020). The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study: Rationale, design and methods. Experimental Gerontology, 110782-N/A. https://doi.org/10.1016/j.exger.2019.110782

Bernabei, Roberto ; Marzetti, Emanuele ; Gambassi, Giovanni ; Calvani, Riccardo ; Gervasoni, Jacopo ; Primiano, Aniello ; Rodriguez-Mañas, Leocadio ; Marini, Federico ; Biancolillo, Alessandra ; Laosa, Olga ; Pedraza, Laura ; Miccheli, Alfredo ; Bourdel-Marchasson, Isabelle ; Regueme, Sophie C. ; Sinclair, Alan J. / The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study: Rationale, design and methods. In: Experimental Gerontology. 2020 ; pagg. 110782-N/A.

@article{9a72c0613ec840c39bd42081247c6d7a,

title = "The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study: Rationale, design and methods",

abstract = "Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact geriatric condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM.",

keywords = "Chemometrics, Metabolic profiling, Metabolomics, Multivariate analysis, Personalized medicine, Sarcopenia, Chemometrics, Metabolic profiling, Metabolomics, Multivariate analysis, Personalized medicine, Sarcopenia",

author = "Roberto Bernabei and Emanuele Marzetti and Giovanni Gambassi and Riccardo Calvani and Jacopo Gervasoni and Aniello Primiano and Leocadio Rodriguez-Ma{\~n}as and Federico Marini and Alessandra Biancolillo and Olga Laosa and Laura Pedraza and Alfredo Miccheli and Isabelle Bourdel-Marchasson and Regueme, {Sophie C.} and Sinclair, {Alan J.}",

year = "2020",

doi = "10.1016/j.exger.2019.110782",

language = "English",

pages = "110782--N/A",

journal = "Experimental Gerontology",

issn = "0531-5565",

publisher = "PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND, OX5 1GB",

}

Bernabei, R , Marzetti, E , Gambassi, G, Calvani, R, Gervasoni, J, Primiano, A, Rodriguez-Mañas, L, Marini, F, Biancolillo, A, Laosa, O, Pedraza, L, Miccheli, A, Bourdel-Marchasson, I, Regueme, SC & Sinclair, AJ 2020, 'The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study: Rationale, design and methods', Experimental Gerontology, pagg. 110782-N/A. https://doi.org/10.1016/j.exger.2019.110782

The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study: Rationale, design and methods. / Bernabei, Roberto ; Marzetti, Emanuele ; Gambassi, Giovanni; Calvani, Riccardo; Gervasoni, Jacopo; Primiano, Aniello; Rodriguez-Mañas, Leocadio; Marini, Federico; Biancolillo, Alessandra; Laosa, Olga; Pedraza, Laura; Miccheli, Alfredo; Bourdel-Marchasson, Isabelle; Regueme, Sophie C.; Sinclair, Alan J.

In: Experimental Gerontology, 2020, pag. 110782-N/A.

Risultato della ricerca: Contributo in rivista › Articolo in rivista

TY - JOUR

T1 - The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study: Rationale, design and methods

AU - Bernabei, Roberto

AU - Marzetti, Emanuele

AU - Gambassi, Giovanni

AU - Calvani, Riccardo

AU - Gervasoni, Jacopo

AU - Primiano, Aniello

AU - Rodriguez-Mañas, Leocadio

AU - Marini, Federico

AU - Biancolillo, Alessandra

AU - Laosa, Olga

AU - Pedraza, Laura

AU - Miccheli, Alfredo

AU - Bourdel-Marchasson, Isabelle

AU - Regueme, Sophie C.

AU - Sinclair, Alan J.

PY - 2020

Y1 - 2020

N2 - Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact geriatric condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM.

AB - Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact geriatric condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM.

KW - Chemometrics

KW - Metabolic profiling

KW - Metabolomics

KW - Multivariate analysis

KW - Personalized medicine

KW - Sarcopenia

KW - Chemometrics

KW - Metabolic profiling

KW - Metabolomics

KW - Multivariate analysis

KW - Personalized medicine

KW - Sarcopenia

UR - http://hdl.handle.net/10807/164733

U2 - 10.1016/j.exger.2019.110782

DO - 10.1016/j.exger.2019.110782

M3 - Article

SP - 110782-N/A

JO - Experimental Gerontology

JF - Experimental Gerontology

SN - 0531-5565

ER -